Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

FLT3/ITD Cooperates with Rac1/DOCK2 to Modulate the Sensitivity of Leukemic Cells to Chemotherapeutic Agents Via Regulation of DNA Repair Pathways

Min Wu, PhD, Li Li, PhD, Max Hamaker, BA, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2016) 128 (22): 2732.

https://doi.org/10.1182/blood.V128.22.2732.2732

Published: 2016

Journal Articles

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

Neil P. Shah, MD PhD, Ronald Paquette, MD, Martin C. Müller, MD, Susanne Saussele, MD, Valentin Garcìa-Gutiérrez, MD, Antonio Jiménez-Velasco, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Francois-Xavier Mahon, MD PhD, Delphine Rea, MD PhD, Patricia Martin-Regueira, MD, Milayna Subar, MD, Li Li, PhD, Jeffrey H. Lipton, MD PhD

Blood (2016) 128 (22): 1895.

https://doi.org/10.1182/blood.V128.22.1895.1895

Published: 2016

Journal Articles

Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line

Rick Sorensen, BS, Sarah Meadows, Anella Yahiaoui, BS, Li Li, PhD, Peng Yue, PhD, Adam Kashishian, BS, Christophe Queva, PhD, Stacey Tannheimer, PhD

Blood (2015) 126 (23): 2482.

https://doi.org/10.1182/blood.V126.23.2482.2482

Published: 2015

Journal Articles

Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib

Sarah Meadows, Sorensen Rick, Yahiaoui Anella, Jia Liu, PhD, Li Li, PhD, Peng Yue, PhD, Christophe Queva, PhD, Stacey Tannheimer, PhD

Blood (2015) 126 (23): 3707.

https://doi.org/10.1182/blood.V126.23.3707.3707

Published: 2015

Journal Articles

DOCK2 Regulates DNA Damage Response and Modulates the Sensitivity to Chemotherapeutic Agents in FLT3/ITD Leukemic Cells

Min Wu, PhD, Li Li, PhD, Max Hamaker, BA, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2015) 126 (23): 3668.

https://doi.org/10.1182/blood.V126.23.3668.3668

Published: 2015

Journal Articles

Combination of Idelalisib and ONO/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors

Stacey Tannheimer, PhD, Jia Liu, PhD, Rick Sorensen, BS, Anella Yahiaoui, BS, Sarah Meadows, Li Li, PhD, Peng Yue, PhD, Kathleen S Keegan, PhD, Jamie Bates, PhD, Daniel Tumas, PhD DVM, Christophe Queva, PhD

Blood (2015) 126 (23): 3697.

https://doi.org/10.1182/blood.V126.23.3697.3697

Published: 2015

Journal Articles

FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment

Hayley S Ma, PhD, Megan E McCray, BA, Courtney M Shirley, PhD, Amy S. Duffield, MD PhD, J Kyle Bruner, Li Li, PhD, Bao Nguyen, M.S., Sarah Greenblatt, PhD, Eric Jung, BS, Peter D. Aplan, MD, Richard J Jones, MD, Donald Small, MD PhD, Gabriel Ghiaur, MD PhD

Blood (2015) 126 (23): 790.

https://doi.org/10.1182/blood.V126.23.790.790

Published: 2015

Journal Articles

DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells

Min Wu, PhD, Max Hamaker, BA, Li Li, PhD, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2014) 124 (21): 3584.

https://doi.org/10.1182/blood.V124.21.3584.3584

Published: 2014

Journal Articles

Dnmt3a Deletion Cooperates with the Flt3-ITD Mutation to Drive Leukemogenesis in a Murine Model

Jennifer L Poitras, BS, Diane Heiser, PhD, Li Li, PhD, Bao Nguyen, M.S., Amy S. Duffield, MD PhD, Christopher Gamper, MD PhD, Donald Small, MD PhD

Blood (2014) 124 (21): 3568.

https://doi.org/10.1182/blood.V124.21.3568.3568

Published: 2014

Journal Articles

Loss of IKKβ Increases the Number and Self-Renewal Capacity of Hematopoietic Stem Cells

Jing Zhang, PhD, Li Li, PhD, Albert S. Baldwin, PhD, Alan D. Friedman, MD, Ido Paz-Priel, MD

Blood (2014) 124 (21): 4345.

https://doi.org/10.1182/blood.V124.21.4345.4345

Published: 2014

Journal Articles

POL5551, a Novel and Potent CXCR4 Antagonist, Enhances Sensitivity to Chemotherapy in an in Vivo Model of High-Risk (HR) Pediatric Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Daniel Magoon, BS, Li Li, PhD, Barbara Romagnoli, PhD, Garry Douglas, PhD, Gerald Tuffin, PharmD/PhD, Johann Zimmermann, PhD, Patrick Brown, MD

Blood (2014) 124 (21): 3707.

https://doi.org/10.1182/blood.V124.21.3707.3707

Published: 2014

Journal Articles

Frequency, Health Care Resource Use (HCRU), and Costs Associated With Skeletal Related Events (SREs) In US Patients With Multiple Myeloma (MM)

Emily Nash Smyth, PharmD, Ilaria Conti, MD, PhD, James Wooldridge, MD, Lee Bowman, PhD, Li Li, PhD, David Nelson, MS, Jin Xie, MS, Daniel E Ball, DrPH

Blood (2013) 122 (21): 2968.

https://doi.org/10.1182/blood.V122.21.2968.2968

Published: 2013

Journal Articles

All- Trans Retinoic Acid Synergizes With FLT3 Tyrosine Kinase Inhibition To Eliminate FLT3/ITD-Expressing Leukemia Cells

Hayley S Ma, Ph.D., Sarah M Greenblatt, PhD, Eric Jung, B.S., Amy S. Duffield, MD, PhD, Li Li, PhD, Gabriel Ghiaur, MD, PhD, Richard J. Jones, Donald Small, MD, PhD

Blood (2013) 122 (21): 3960.

https://doi.org/10.1182/blood.V122.21.3960.3960

Published: 2013

Journal Articles

Canonical NF-κB Signalling Is a Potential Target in FLT3/ITD AML.

Jing Zhang, PhD, Li Li, PhD, Alan D. Friedman, M.D., Donald Small, MD, PhD, Ido Paz-Priel, M.D.

Blood (2012) 120 (21): 2447.

https://doi.org/10.1182/blood.V120.21.2447.2447

Published: 2012

Journal Articles

TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia

Hayley S Wall, B.S., Bao Nguyen, M.S., Li Li, PhD, Sarah M Greenblatt, PhD, Patrick Brown, MD, Mark J. Levis, MD, PhD, Donald Small, MD, PhD

Blood (2012) 120 (21): 866.

https://doi.org/10.1182/blood.V120.21.866.866

Published: 2012

Journal Articles

Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

Holbrook E Kohrt, MD, PhD, Lu Tian, PhD, Li Li, PhD, Ash A. Alizadeh, MD, PhD, Sue Hsieh, PhD, Samuel Strober, MD, Minnie Sarwal, MD PhD, Robert Lowsky, MD

Blood (2012) 120 (21): 4190.

https://doi.org/10.1182/blood.V120.21.4190.4190

Published: 2012

Journal Articles

Generation of a FLT3 Kinase Domain Point Mutation (D835Y equivalent) Knock-in Mouse Confers Less Aggressive Disease Compared with FLT3 Internal Tandem Duplication (ITD) Mice

Emily Bailey, DVM, Li Li, PhD, David Huso, D.V.M., Ph.D., Hayley S Wall, Donald Small, MD, PhD

Blood (2011) 118 (21): 924.

https://doi.org/10.1182/blood.V118.21.924.924

Published: 2011

Journal Articles

Knock-in of a FLT3 Internal Tandem Duplication Mutation Cooperates with a NUP98-HOXD13 Fusion to Generate Acute Myeloid Leukemia

Sarah M Greenblatt, Li Li, PhD, Christopher Slape, PhD, Rachel L Novak, PhD, Amy S. Duffield, MD, PhD, Bao Nguyen, M.S., David Huso, D.V.M., Ph.D., Michael J. Borowitz, MD, PhD, Peter Aplan, MD, Donald Small, MD, PhD

Blood (2011) 118 (21): 865.

https://doi.org/10.1182/blood.V118.21.865.865

Published: 2011

Journal Articles

Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia

Edward Allan R. Sison, MD, Daniel Magoon, Li Li, PhD, Rachel E. Rau, MD, Colleen E. Annesley, MD, Donald Small, MD, PhD, Patrick A. Brown, MD

Blood (2011) 118 (21): 1410.

https://doi.org/10.1182/blood.V118.21.1410.1410

Published: 2011

Journal Articles

Statin Treatment Prevents FLT3 Glycosylation and Overcomes Resistance to FLT3 Tyrosine Kinase Inhibitors

Allen Williams, PhD, Li Li, PhD, Bao Nguyen, M.S., Patrick Brown, MD, Mark J. Levis, MD, PhD, Donald Small, MD, PhD

Blood (2011) 118 (21): 1421.

https://doi.org/10.1182/blood.V118.21.1421.1421

Published: 2011

NARROW

FLT3/ITD Cooperates with Rac1/DOCK2 to Modulate the Sensitivity of Leukemic Cells to Chemotherapeutic Agents Via Regulation of DNA Repair Pathways

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line

Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib

DOCK2 Regulates DNA Damage Response and Modulates the Sensitivity to Chemotherapeutic Agents in FLT3/ITD Leukemic Cells

Combination of Idelalisib and ONO/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors

FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment

DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells

Dnmt3a Deletion Cooperates with the Flt3-ITD Mutation to Drive Leukemogenesis in a Murine Model

Loss of IKKβ Increases the Number and Self-Renewal Capacity of Hematopoietic Stem Cells

POL5551, a Novel and Potent CXCR4 Antagonist, Enhances Sensitivity to Chemotherapy in an in Vivo Model of High-Risk (HR) Pediatric Acute Lymphoblastic Leukemia (ALL)

Frequency, Health Care Resource Use (HCRU), and Costs Associated With Skeletal Related Events (SREs) In US Patients With Multiple Myeloma (MM)

All- Trans Retinoic Acid Synergizes With FLT3 Tyrosine Kinase Inhibition To Eliminate FLT3/ITD-Expressing Leukemia Cells

Canonical NF-κB Signalling Is a Potential Target in FLT3/ITD AML.

TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia

Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

Generation of a FLT3 Kinase Domain Point Mutation (D835Y equivalent) Knock-in Mouse Confers Less Aggressive Disease Compared with FLT3 Internal Tandem Duplication (ITD) Mice

Knock-in of a FLT3 Internal Tandem Duplication Mutation Cooperates with a NUP98-HOXD13 Fusion to Generate Acute Myeloid Leukemia

Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia

Statin Treatment Prevents FLT3 Glycosylation and Overcomes Resistance to FLT3 Tyrosine Kinase Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only